Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack

15-sep-2019 | Revista: Clinical Cancer Research

Salas-Benito D (1,2), Melero I (2,3,4), Ponz-Sarvise M (5,4,6).

(1) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(2) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(3) Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain.
(4) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
(5) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(6) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.


No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.

CITA DEL ARTÍCULO  Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17